US Patent 12,433,907 (Maribavir): Scope of Claims, Claim-Chart Drivers, and US Patent Landscape for CMV Treatment in Transplant Recipients on Phenytoin/Phenobarbital
United States Patent 12,433,907 is a method-of-use patent that targets a specific clinical intersection: maribavir (1200 mg orally twice daily) for treating cytomegalovirus (CMV) infection in transplant recipients who are concurrently exposed to an immunosuppressant and are taking an anticonvulsant restricted to phenytoin or phenobarbital. The claim set is claim-dependent, with the strongest infringement hooks being (i) the 1200 mg BID maribavir regimen, (ii) the constrained anticonvulsant selection (phenytoin or phenobarbital), (iii) adult/adolescent eligibility and weight minimum, (iv) refractory status to standard-of-care antivirals, and (v) transplant type (hematopoietic stem cell vs solid organ) plus specific immunosuppressant exemplars and monitoring/dose-adjustment steps.
What is US Patent 12,433,907 and what is it claiming for maribavir?
Core subject matter (independent claim 1):
A method of treating CMV infection by administering maribavir 1200 mg orally twice daily to a transplant recipient who is concomitantly exposed to or receiving an immunosuppressant and also receives an anticonvulsant selected from phenytoin or phenobarbital.
Claim 1 scope anchor points that define infringement risk
- Drug and dose form/regimen: “maribavir” at 1200 mg orally twice daily.
- Population: “patient suffering” CMV infection and is a transplant recipient.
- Concurrent therapies:
- Immunosuppressant exposure (generic functional requirement in claim 1).
- Anticonvulsant constraint: only phenytoin or phenobarbital.
- Treatment intent: “method of treating CMV infection.”
Dependent claims 2–20 narrow in ways that can create partial noninfringement opportunities for designers
- Anticonvulsant specificity: claim 2 (phenytoin) and claim 3 (phenobarbital).
- Eligibility gating: claim 4 limits to patients ≥12 years and ≥35 kg.
- Refractory requirement: claim 5 requires refractoriness to ganciclovir/valganciclovir/cidofovir/foscarnet.
- Transplant type: claim 6 (hematopoietic stem cell transplant) and claim 7 (solid organ transplant).
- Immunosuppressant examples: claims 8–11 name cyclosporine, everolimus, sirolimus, tacrolimus.
- Tacrolimus dosing stability: claim 12 restricts tacrolimus to a stable twice-daily regimen with total daily dose 0.5 to 16 mg.
- Anticonvulsant dosing specificity:
- claim 14: phenobarbital 100 mg once daily.
- claim 16: phenytoin 300 mg once daily.
- Therapeutic drug monitoring and dose adjustment:
- claim 17 monitoring immunosuppressant drug levels throughout maribavir treatment.
- claim 18 timing: after initiation and after discontinuation of maribavir.
- claim 19–20: adjusting immunosuppressant dose (with corresponding limitations tying to claim 18).
Practical effect: Claim 1 is broadest; the rest are narrower fallbacks. From a licensing or litigation posture, the broadest claim defines the litigation “center of gravity,” while narrower claims define how strong infringement is against specific real-world clinical protocols.
How broad is Claim 1 versus the dependent claims: what elements are hardest to satisfy in practice?
Claim 1 breadth drivers (strongest infringement likelihood)
- Concomitant immunosuppressant is not limited to a named drug in claim 1. Any immunosuppressant exposure suffices in that functional requirement.
- Transplant recipient is not limited to a particular transplant type in claim 1.
- Anticonvulsant is limited only to two drugs (phenytoin, phenobarbital), which reduces the universe of noninfringement but also creates a clear design-around by avoiding those anticonvulsants.
Claim 1 hard-to-satisfy constraints (design-around and partial defense levers)
- The clinician must use maribavir at 1200 mg orally twice daily.
- The patient must be taking phenytoin or phenobarbital concurrently or be “concomitantly exposed” to it.
- The clinical context must match “transplant recipient suffering CMV infection.”
Dependent claim strengthening (how claim language narrows real-world infringing protocols)
- Claim 4 (age/weight): if the patient is under 12 or under 35 kg, dependent claims are harder to assert. Claim 1 may still be asserted unless claim 4 is required.
- Claim 5 (refractory status): requires documented refractoriness to specific antivirals. This is a common evidentiary issue and can constrain dependent claim reach.
- Claims 6–7 (transplant type): affects which patient populations get directly pulled into litigation.
- Claims 8–11 (specific immunosuppressants) plus claim 12 (tacrolimus dose stability and range): creates an evidentiary narrowing for tacrolimus-based subpopulations.
- Claims 14 and 16 (phenobarbital 100 mg QD; phenytoin 300 mg QD): tight dosing windows can make dependent claims narrower than clinicians’ real dosing variability.
- Claims 17–20 (monitoring and dose adjustments): these add operational steps that are highly fact-dependent (documentation from charts/pharmacy management protocols).
What is the claim scope in clinical terms for maribavir + phenytoin/phenobarbital in transplant CMV?
Clinically mapped elements
- Condition: CMV infection.
- Setting: transplant recipients (hematopoietic or solid organ).
- Concurrent drug-interaction landscape:
- Phenytoin/phenobarbital are enzyme inducers that can affect exposure to co-administered drugs. The patent claims the method of treating CMV infection using maribavir in the presence of those anticonvulsants.
- Immunosuppressants are concurrently administered; the patent contemplates monitoring and potentially adjusting immunosuppressant drug levels/doses.
Infringement measurement focus
- Dose accuracy (maribavir 1200 mg BID).
- Medication reconciliation showing concomitant phenytoin or phenobarbital.
- CMV diagnosis and “treatment” intent.
- For dependent claims: documentation supporting refractory status, dosing amounts, monitoring steps, and transplant type.
How many claim variants exist and which claim dependencies create the strongest infringement tiers?
Claim dependency graph (functional tiers)
- Tier 1: Claim 1 (baseline).
- Tier 2: anticonvulsant-specific Claims 2–3.
- Tier 3: eligibility gating (Claim 4), refractoriness (Claim 5), transplant type (Claims 6–7).
- Tier 4: immunosuppressant-specific (Claims 8–11), tacrolimus stability and dosing range (Claim 12).
- Tier 5: anticonvulsant dose specifics (Claims 13–16).
- Tier 6: operational/monitoring protocols (Claims 17–20).
Litigation posture for value
- Largest asserted universe: Claim 1 (if facts fit).
- Most proof-intensive asserted variants: Claims 5, 12, 14, 16, 17–20 due to chart-level evidentiary requirements.
What patents protect maribavir methods in transplant CMV patients on enzyme inducers in the US?
No complete US patent “landscape” can be produced from the prompt alone because the necessary bibliographic data for US 12,433,907 (assignee, filing/priority chain, application publication, and patent family members) is not provided. A “landscape” without those identifiers would risk generating inaccurate listings and claim overlaps.
What can be stated from the claims provided:
- The patent’s inventive focus is a method of treatment with maribavir in transplant recipients who are on phenytoin or phenobarbital, including dose regimen and optional monitoring/dose adjustment steps.
- The claim structure suggests the patent is intended to deter generic and competitive entry by capturing real-world co-medication scenarios, particularly where drug-drug interactions would otherwise push clinicians to alter therapy.
Because the prompt does not include patent bibliographic details or related-document identifiers, a reliable enumeration of overlapping US patents (other methods, formulations, or drug-drug interaction guidance patents) cannot be completed without generating potentially false citations.
How does US 12,433,907 compare with typical maribavir patent families: formulation vs method-of-use barriers?
What this patent is: method-of-use with regimen and patient-therapy context.
What this patent is not (based on provided claim text):
- No explicit formulation composition limitation.
- No explicit dosage form, coating, or manufacturing process limitation.
- No explicit “use as” in a way that claims specific packaging or formulation technologies.
Implication
- A generic maribavir product with the same active ingredient and dosage form could still be exposed to method-of-use infringement if marketed/used for the patented method and if the clinician/prescriber administers the patented regimen in the patented patient context.
- The most direct infringement scenario is a label or practice aligned with maribavir 1200 mg BID in transplant CMV patients on phenytoin/phenobarbital, especially where monitoring/dose adjustment is performed.
What are the most likely design-around strategies under the claim language?
Based solely on the claim limitations you provided:
- Avoid phenytoin and phenobarbital
- Switching to a different anticonvulsant would fall outside the anticonvulsant constraint in claim 1 (and thus also outside dependent claims 2–3, 13–16).
- Change the maribavir regimen
- Using a different maribavir dose or schedule than 1200 mg orally twice daily aims at the hard dose regimen limitation.
- Use in patients outside dependent eligibility gates
- Dependent claims 4 and 5 can potentially be avoided by treating patients who do not meet age/weight thresholds or do not qualify as refractory to the listed antivirals.
- Avoid the monitoring/dose-adjustment operational steps
- If conduct is structured to avoid “monitoring immunosuppressant drug levels throughout treatment” and the specified timing and dose-adjustment steps, dependent claims 17–20 become harder to prove.
These strategies are conceptually constrained by clinical realities, but they map directly onto the claim language.
What does the claim imply for Orange Book status and generic entry risk?
A complete Orange Book analysis requires the drug product’s NDC-level listing, listed patents, and expiration dates. The prompt does not provide the Orange Book entries for maribavir, nor whether US 12,433,907 is listed for specific NDA(s)/strengths.
Claim-based risk conclusion without Orange Book data:
- If the patented method is practiced after generic approval and if the generic product is used at 1200 mg BID in the patented transplant+anticonvulsant context, method-of-use theories may create entry and litigation exposure even when formulation patents do not apply.
- If the patent is listed (or otherwise asserted via litigation) for the relevant product, Paragraph IV and/or injunction leverage becomes more plausible. But listing status cannot be asserted from the provided text.
Key Takeaways
- US 12,433,907 claims a maribavir method of treating CMV infection in transplant recipients who are concomitantly exposed to immunosuppressants and also receive phenytoin or phenobarbital.
- The independent claim is centered on maribavir 1200 mg orally twice daily plus the two-drug anticonvulsant constraint and the transplant CMV context.
- Dependent claims materially narrow infringement through age/weight, refractoriness to named antivirals, transplant type, immunosuppressant selection (including tacrolimus dose range and stability), specific anticonvulsant doses, and monitoring/dose-adjustment steps.
- The claim structure creates clear, language-driven design-around opportunities: avoid phenytoin/phenobarbital, alter maribavir dosing regimen, or avoid the specific monitoring/dose-adjustment steps (for dependent claims).
- A complete US “patent landscape” (count of overlapping US patents, family member mapping, litigation status, expiration timelines, and Orange Book listing) cannot be reliably generated from the prompt alone because essential patent bibliographic identifiers and FDA listing identifiers are not provided.
FAQs
1) Does US 12,433,907 cover maribavir use with any anticonvulsant?
No. Claim 1 limits the anticonvulsant to phenytoin or phenobarbital.
2) Is tacrolimus required to be one of the immunosuppressants?
No for claim 1. Tacrolimus is one exemplary immunosuppressant in dependent claim 11, and claim 12 adds dosing stability and range specifics.
3) Is “refractory to ganciclovir/valganciclovir/cidofovir/foscarnet” required for infringement of claim 1?
No. That limitation appears in dependent claim 5.
4) Can monitoring and dose adjustment change infringement exposure?
Yes. Monitoring/dose-adjustment limitations are in dependent claims 17–20 and require matching conduct and documentation.
5) What is the single most important regimen parameter in the independent claim?
The method requires maribavir 1200 mg orally twice daily.
References
- Provided in prompt: Claims 1–20 for US Patent 12,433,907 (text supplied by user).
